Paradoxically, high ADGRL4/ELTD1 expression in patients treated with systemic anti-cancer treatment correlated with improved overall survival (head and neck squamous carcinoma, renal, colorectal and ovarian cancers)4. Here, ADGRL4 is linked to ovarian carcinoma.